Sanofi and Regeneron face a high-risk test for Dupixent

Dupixent is already forecast to become an $18bn drug by 2028, according to Evaluate Pharma sellside consensus, but its makers Sanofi and Regeneron clearly want more. The next potential avenue for expansion is chronic obstructive pulmonary disease, where the partners have a high-risk/high-reward readout coming.